Oramed Pharmaceuticals In... (ORMP)
Oramed Pharmaceuticals Inc. (ORMP) Stock Price, Analysis & Data
| Бид | 3.14 |
| Рыночная капитализация | 182.2M |
| Выручка (TTM) | n/a |
| Чистая прибыль (TTM) | 174.06M |
| Бета | 1.16 |
| EPS (TTM) | 4.24 |
| P/E (TTM) | 1.03 |
| Прогнозный P/E | -54.75 |
| P/B (TTM) | 0.57 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 12, 2026 |
| Аск | 5.55 |
| Объём торгов | 150,083 |
| Ср. объём (20д) | 295,298 |
| Открытие | 4.35 |
| Пред. закрытие | 4.27 |
| Диапазон дня | 4.30 - 4.45 |
| Диапазон за 52 недели | 1.98 - 5.19 |
| Аналитики | n/a |
| Целевая цена | 6.25 (42.69%) |
| Дивиденды | $0.25 (5.85%) |
| Дата отсечки | 16 янв. 2026 г. |
О компании ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporat...
Финансовые результаты
В 2025 году выручка Oramed Pharmaceuticals составила 2M — это рост на undefined% к прошлогодним 0. Прибыль составила 64.05M — это снижение на -436.04%.
Финансовая отчётностьПрогноз аналитиков
По 1 оценкам аналитиков средний рейтинг акций ORMP — «null». Прогноз цены на 12 месяцев — 6.25, это потенциал роста на 42.69% от последней цены.
Прогнозы по акцииСюрприз в отчёте
Аналитики ждут выручку ... Улучшить тариф
3 месяцев назад · Simply Wall St.
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny StocksThe market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investment...
4 месяцев назад · Simply Wall St.
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy InvestorsThe market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock'...
